Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orphan Drug Policy Changes To Be Considered Under US FDA's FY 2019 Budget Proposal

Executive Summary

Proposed $20m funding boost for rare disease development includes review of orphan incentives, including how to potentially stimulate development in ultra-orphan diseases.
Advertisement

Related Content

Opioids, Old Initiatives Dominate FY 2020 US FDA Funding Increase
Clinical Trial Reform Is A Focus For CDER's 2019 Guidance Agenda
Gene Therapy 'Cassettes' Could Speed, Cheapen Manufacturing, Gottlieb Says
House Appropriators Warn US FDA: Stop Working On Electronic Labeling Rule
Orphan Drug Development: Could We Be Seeing The End Of P Values?
FDA Highlights Advanced Drug Manufacturing Approaches In Budget Plan
Trump's Budget Surprise: FDA Gains 13% Increase
US FDA Doesn't Support Creating Ultra-Orphan Designation
Orphan Designations For Pediatric Subgroups Of Common Diseases To End
Orphan Drug Pricing Heading To Negotiating Table in US?

Topics

Advertisement
UsernamePublicRestriction

Register

PS122841

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel